Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

spectrollmicro 22 posts  |  Last Activity: May 25, 2016 10:38 AM Member since: Feb 10, 2016
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Phil's comments on AACR $ misc

    by mangymutt Mar 17, 2016 12:25 AM
    spectrollmicro spectrollmicro Mar 17, 2016 2:52 PM Flag

    Geron could have never afforded or arrived at current understanding and these multiples of clinicals if not for the Janssen agreement. The money already spent on this venture would have needed a 50 million stock secondary to raise the funds to only arrive at this moment, let alone future spending.

    It just takes time and lots of resources which is what JNJ/Janssen has brought

    I agree completely

    Sentiment: Strong Buy

  • spectrollmicro spectrollmicro May 19, 2016 7:06 PM Flag

    One has to wonder why any person who could qualify for Imetelstat, does not request their doctor to petition the FDA for emergency use authorization, in contrast to using other drugs which fail to do little more than an aspirin does for a migraine. That is giving many drugs to much credit even at that comparison.

  • spectrollmicro spectrollmicro Apr 27, 2016 8:53 AM Flag

    Isn't Jakafi widely considered a placebo by most of the informed hematological field now? It would be interesting to know how many law suits would be filed for malpractice if the patients really knew the incredible chance of survival, had they been treated with Imetelstat instead of Jakafi that their doctors forced on them based on their bias and not patient interest in best therapy available.

    Imetelstat is potentially available through FDA emergency authorization application.

    Very sad that patients must die for that bias, when a therapy that allows for life exists by using imetelstat

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro Mar 20, 2016 11:26 AM Flag

    While MEIP mgt plays footsy with themselves and further demonstrate their incompetence as they delay their Pracinostat phase 3 , MEIP mgt cares not as they fail. Their phase 3 should have been started last year in Nov but mgt gave the finger to investors.

    All the while.........

    CPXX Celator with debt of $15.3 million and $24 million in cash, gets 9.5 months median with their AML drug and their stock goes to $10 with tgt $20

    MEIP with no debt and $54 million in cash, gets 16 months median , a 6.5 month improvement over with Parcinostat + azacitidiine for their AML study, decides to start a phase 3 and their stock drops to $0.87 all time low on Feb12th one month earlier with tgt of $3

    Did I mention that MEIP pracinostat has proven superior results by 70% median 16 median over CPXX CPX-351, 9.5 month median
    But of course MEIP mgt team of experts care not

  • spectrollmicro spectrollmicro Apr 4, 2016 2:02 PM Flag

    The comments at the Needham Conference next Tuesday April 12th @ 3ET , could be pivotal for share price. Regardless, OS has already been 56% and the mean survival longer than any previous drug for elderly AML patients including Celgene's Vidaza. This would seem to be enough to trigger Celgene to partner in the P3 pracinostat + azacitidine(Vidaza) and then there is the mitochondrial inhibitor of MEIP that is preparing P 2 they could also partner in development.

    This low price with no debt + cash, & late stage drug makes little sense and would seem to be promising enough for another company to be very interested.

    The registration in Delaware per 8K, seems to be another move to reduce costs even more or possibly position for a simple alternate reason.

    Sentiment: Strong Buy

  • Reply to

    AML

    by vm779460 Mar 15, 2016 8:06 AM
    spectrollmicro spectrollmicro Mar 16, 2016 11:13 AM Flag

    CPXX continues higher after announcing inferior results to Pracinost + atazacitidine combination therapy.

    MEI management feels no compunction to make any press release based on their own superior results. Volume on stock & price looks like MEI has announced closing door as the stock trades below cash with no debt and getting ready to start ME-344 phase 2 cervical and other cancers in the next couple months and phase 3 clinical for highly successful pracinostat + azacitidine for AML a couple months later

    Unbelievable !

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro May 5, 2016 8:44 AM Flag

    18 months now the mean as of March 11,2016 which would mean 20 months now. OS has not been reached for the 27 patients( that is a good thing) This means the patients are living much longer than any other therapy. Pracinostat / Azacitidine is proving to be far superior which only gave 10 months mean survival

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro Mar 31, 2016 12:29 PM Flag

    In this 2nd quarter MEIP i to start a Phase 2 clinical study of ME-344 in combination with topotecan (trade name Hycamtin®) in patients with small cell lung and ovarian cancers In addition , Phase 3 clinical Parcinostat + azacitidine (Vidaza) for elderly AML patients is scheduled to start in the second half of 2016

  • Reply to

    I am desvastated

    by lam.tuongnguyen Feb 10, 2016 11:46 PM
    spectrollmicro spectrollmicro Apr 12, 2016 3:17 PM Flag

    The problem with that aspect of the trial was clinical construct and proper education of side effects to the physicians. The side effects for such a young group, who cry when their cereal is not perfect or they are told no, was not made clear to them. The long term study has in fact shown they could have seen remission had they continued through the end of the clinical. The AML patients who continued, are alive now because of their tenacity and dedication to living longer. Oh yes, they were mature adults who have a better understanding of adversity.

    Now an AML drug which can help many extend life is on it's way to phase 3, a mitochondrial inhibitor on it's way to phase2 and still more cash than company market cap.

    As for the drop in share price, that was all institutions bailing before all data was made known. Another example of uneducated traders who expected a quick turn for money they didn't earn.

    Sentiment: Strong Buy

  • spectrollmicro spectrollmicro May 5, 2016 9:05 AM Flag

    These buyout headlines highlight how ridiculous the current price is for GERN and its' ground breaking therapy imetelstat which has proven Complete Remissions in multiple patient cases. Instead of being priced as the ground breaking therapy and platform drug, it is priced lower than a company selling placebo for drug clinicals.

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro Mar 15, 2016 9:55 AM Flag

    It would make sense for CELG to partner with MEI to make their own drug azacitidine (Vidaza) more marketable. Since pracinostat + azacitidine (Vidaza) combination is in MEIP phase 2 and phase 3 that is starting soon. Vidaza by itself is not an answer to AML, but when combined with pracinostat is very successful..

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro Apr 14, 2016 9:40 AM Flag

    If management wants to really confirm MEIP future, they should start buying shares in the open market. A 15,000 or larger purchase would signal they chose to own with their own money. If their pipeline is impressive and has great viability, then insider buying would be a sign of enormous confidence.

    If they would talk a little about securing a partner or indicate there is interest from potential partners, again it would be a catalyst for the stock price and a positive future.

    Sentiment: Strong Buy

  • spectrollmicro spectrollmicro May 25, 2016 10:38 AM Flag

    Interesting that it says phase 3 in the Purpose section

    Myelodysplastic Syndromes
    Drug: Imetelstat
    Drug: Placebo
    Phase 3

    Sentiment: Strong Buy

  • spectrollmicro by spectrollmicro Mar 30, 2016 8:25 AM Flag

    The Needham Healthcare Conference on April 12th @ 3:00 pm ET should give some update. Hopefully no time will be wasted at the conference with BOD and mgt resume summary. If they can spend some time updating on significant drug development facts and potential for partnership, it would be much more constructive .

  • Reply to

    Wedbush

    by spectrollmicro Apr 19, 2016 9:32 AM
    spectrollmicro spectrollmicro Apr 19, 2016 10:16 AM Flag

    No there was no mention of partnering, nor was there any question regarding financial concerns. The mean is now over 17 months and the clinical is to start as advertised. The most significant point addressed was the comparison of OS and mean survival to other drugs by competitors. Pracinostat / azacitidine combo continues to be far superior to any other drugs. MEIP also posted the results from a survey they did of doctors. They asked doctors if the longer life results seen with pracinostat would cause them to switch from other therapy and over 75% of doctors said they would switch if it were approved. I would also, think those same doctors would try to get their patients in the phase 3 for the extended life benefits or maybe even apply to FDA for compassionate use, since the difference is over twice mean in some cases.

  • spectrollmicro by spectrollmicro Apr 19, 2016 9:32 AM Flag

    One can assume Wedbush must have not have listened to the last Needham conference call or not understood what was said. Maybe Wedbush had a teen age son listen and then tell them what he got out of the call. Regardless, the Wedbush call leaves a question about their ability to accurately understand bio-tech drug development. To reduce opinion in light of recent news seems a huge disconnect with reality.

    Sentiment: Strong Buy

  • Reply to

    True validity would be insider buys

    by spectrollmicro Apr 14, 2016 9:40 AM
    spectrollmicro spectrollmicro Apr 14, 2016 10:42 AM Flag

    It would also help if MEIP Mgt would reiterate the Orphan Drug Designation which was assigned to pracinostat back in Feb, 2014 and then specify how or if the FDA is looking at it for Accelerated Approval process given the superior results to date. This may be one reason for the phase 3 being pushed out until second half of 2016 so the realized mean survival will be maximized . In 2014 MEI was indicating it was working closely with the FDA regarding the end point to fast track pracinostat

    Sentiment: Strong Buy

  • Reply to

    AML

    by vm779460 Mar 15, 2016 8:06 AM
    spectrollmicro spectrollmicro Mar 15, 2016 9:07 AM Flag

    the difference is pracinostat + azacitidine results in AML of 16 months median & 56% OS just going into phase 3 so an investor gets in here, at this ridiculous low price $1.20 in contrast to CPXX

    Sentiment: Strong Buy

  • Reply to

    Vivo Ventures sold more this week

    by spectrollmicro Apr 15, 2016 2:42 PM
    spectrollmicro spectrollmicro Apr 16, 2016 12:47 PM Flag

    13D/A filed April 14, 2016 reflecting shares held as of April 14, 2016

    (Date of Event which Requires Filing of this Statement)

    Includes 2,006,662 shares of common stock held of record by Vivo Ventures Fund VII, L.P., and 43,737 shares of common stock held of record by Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the sole general partner of both of the Vivo VII Funds and may be deemed to beneficially own such shares, and disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.

    (2) Based upon 34,155,997 shares of common stock outstanding as of February 4, 2016, as reported in the Issuer’s quarterly report on Form 10-Q for the quarter ended December 31, 2015, filed on February 5, 2016.

  • spectrollmicro spectrollmicro Apr 5, 2016 6:28 AM Flag

    You are correct about the 3:40 ET is the listed time for Needham Conf . Thank you

SIGA
0.75+0.0450(+6.38%)May 27 3:58 PMEDT